REAL-WORLD COMPARISON OF HEALTHCARE COSTS AMONG PATIENTS WITH TYPE 2 DIABETES TREATED WITH DULAGLUTIDE VS. LIRAGLUTIDE IN THE UNITED STATES

被引：0
|
作者：
Mody, R. [1 ]
Huang, Q. [2 ]
Yu, M. [3 ]
Patel, H. [1 ]
Zhao, R. [2 ]
Grabner, M. [2 ]
Lando, Fernandez L. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] HealthCore Inc, Wilmington, DE USA
[3] Eli Lilly & Co, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.520
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB89
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [1] HEALTH CARE RESOURCE UTILIZATION AND COSTS OF PATIENTS WITH TYPE 2 DIABETES TREATED WITH DULAGLUTIDE VS. EXENATIDE QW OR LIRAGLUTIDE IN THE US
    Mody, R.
    Alatorre, C.
    Yu, M.
    Lando, Fernandez L.
    Davis, B.
    Juneau, P.
    VALUE IN HEALTH, 2017, 20 (05) : A178 - A178
  • [2] Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
    Kenichi Tanaka
    Yosuke Okada
    Akemi Tokutsu
    Yoshiya Tanaka
    Scientific Reports, 12
  • [3] Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
    Tanaka, Kenichi
    Okada, Yosuke
    Tokutsu, Akemi
    Tanaka, Yoshiya
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] A FIRST LOOK: REAL-WORLD COMPARISON OF UTILIZATION AND EFFECTIVENESS OF ALBIGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES MELLITUS PATIENTS IN THE UNITED STATES
    Buysman, E. K.
    Sikirica, M., V
    Thayer, S. W.
    Bogart, M.
    DuCharme, M.
    Joshi, A., V
    VALUE IN HEALTH, 2017, 20 (05) : A164 - A165
  • [5] REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE COSTS AMONG PATIENTS WITH ADHESIVE CAPSULITIS IN THE UNITED STATES
    Tse, J.
    Banerji, T.
    Wang, E. J.
    Near, A.
    Davis, J.
    Hurley, D.
    VALUE IN HEALTH, 2022, 25 (07) : S342 - S342
  • [6] METFORMIN DOSAGE PATTERNS IN TYPE 2 DIABETES PATIENTS IN A REAL-WORLD HEALTHCARE SETTING IN THE UNITED STATES
    Mahabaleshwarkar, R.
    DeSantis, A.
    VALUE IN HEALTH, 2019, 22 : S173 - S174
  • [7] REAL WORLD EFFECTIVENESS OF DULAGLUTIDE AMONG PATIENTS WITH TYPE 2 DIABETES
    Mody, R.
    Yu, M.
    Fernandez, L.
    Shui, A.
    Kallenbach, L.
    Slipski, L.
    de Oliveira, Piras C.
    VALUE IN HEALTH, 2017, 20 (05) : A164 - A164
  • [8] Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
    Qian Li
    Abhishek Chitnis
    Mette Hammer
    Jakob Langer
    Diabetes Therapy, 2014, 5 : 579 - 590
  • [9] Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
    Li, Qian
    Chitnis, Abhishek
    Hammer, Mette
    Langer, Jakob
    DIABETES THERAPY, 2014, 5 (02) : 579 - 590
  • [10] REAL-WORLD ECONOMIC OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) TREATED WITH DULAGLUTIDE (DU) VS. BASAL INSULIN (BI) IN THE US: THE DISPEL™ STUDY
    Mody, R.
    Huang, Q.
    Yu, M.
    Zhang, X.
    Wang, L.
    Grabner, M.
    Patel, H.
    VALUE IN HEALTH, 2019, 22 : S149 - S150
12345